Tamsulosin ( DrugBank: Tamsulosin )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 13 | Multiple sclerosis/Neuromyelitis optica | 1 |
13. Multiple sclerosis/Neuromyelitis optica
Clinical trials : 3,340 / Drugs : 2,163 - (DrugBank : 383) / Drug target genes : 241 - Drug target pathways : 238
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05439902 (ClinicalTrials.gov) | October 5, 2022 | 27/6/2022 | Efficacy of Alpha-blockers (Tamsulosin) in the Treatment of Symptomatic Dysuria in Multiple Sclerosis in Women | Efficacy of Alpha-blockers (Tamsulosin) in the Treatment of Symptomatic Dysuria in Multiple Sclerosis in Women | Multiple Sclerosis;Dysuria;Lower Urinary Tract Symptoms;Voiding Dysfunction;Urinary Retention | Drug: Tamsulosin;Drug: Placebo | Centre Hospitalier Universitaire de Nimes | NULL | Recruiting | 18 Years | N/A | Female | 60 | N/A | France |